OraPharma, Inc. Expands Commitment to Academic Community by Renewing ARESTIN® Student Access Program

Posted: August 13, 2009
OraPharma, Inc. Expands Commitment to Academic Community by Renewing ARESTIN® Student Access Program
 
Innovative Program Supplies Participating Dental and Dental Hygiene Schools with Product and Course Materials for ARESTIN® Hands-On Instruction
 
Warminster, PA – August 13, 2009 – OraPharma, Inc., a specialty oral health company dedicated to bringing scientifically and technologically superior products to the dental community, including ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg, recently expanded its commitment to providing educational support and training to dental and dental hygiene schools by renewing the ARESTIN® Student Access Program and by creating a new Professional Affairs Team to provide field support and instructor training for the program.
 
The ARESTIN® Student Access Program was implemented a few years ago as the result of discussion and collaboration between OraPharma and the directors of leading dental and dental hygiene schools. According to ARESTIN® Product Director Ben Sandefur, “Our mutual goal was to develop a program that would provide educational programming and hands-on training so that dental and dental hygiene students can learn how to appropriately incorporate locally administered antibiotics like ARESTIN® as part of a comprehensive periodontal disease treatment protocol.”
 
During the 2008-2009 school year, 118 dental and dental hygiene schools and over 2,800 dental and dental hygiene students participated in the ARESTIN® Student Access Program.
 
Enrollment for the 2009-2010 program is available to all accredited two- or four-year dental and dental hygiene schools as well as periodontal specialty programs that include instruction on the use of ARESTIN® as part of a comprehensive periodontal treatment protocol. Participating schools will receive the following ARESTIN® Student Access Program materials:
 
·         ARESTIN® Trial Kits containing 12 ARESTIN® cartridges for clinical use by each participating student. 
 

·         Faculty Education Kits containing valuable clinical and patient resources regarding periodontal therapy and ARESTIN®, as well as educational content for classroom lectures and demonstration product for hands on laboratory to ensure each student is able to practice placing ARESTIN® prior to treating patients.
 
  • Student Education Kits including valuable clinical and patient education resources regarding periodontal therapy and ARESTIN®.

 
·         Two ARESTIN® handles at no charge and the ability to order additional discounted ARESTIN® handles ($32.00 each) for all participating students
 
The OraPharma, Inc Professional Affairs Team will provide enhanced support and introduce additional academic programs to dental and hygiene schools. This team will also provide best practices training and education for course directors in schools participating in the ARESTIN® Student Access Program.
 
“The ARESTIN® Student Access Program helps ensure that ARESTIN® will continue to be widely available for clinical use by all dental and dental hygiene school students. Today’s students represent the next generation of oral health professionals,” explained Sandefur. “It’s important that they have training and experience with the most common periodontal disease options upon graduation.”
 
Dental and dental hygiene school faculty who wish to participate in the ARESTIN® Student Access Program can get more information and register for the program at https://www.myarestin.com/studentaccess.  If you require more information, please contact the OraPharma, Inc Professional Education team at 1-888-553-6010 extension 0627.-
 
About OraPharma, Inc.
 
OraPharma, Inc. is a specialty pharmaceutical company that discovers, develops, and commercializes therapeutics for the treatment of periodontal disease at various phases of progression. ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg (www.arestin.com) is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. OSSIX® PLUS™ (resorbable collagen membrane) is used in guided bone regeneration (GBR) and guided tissue regeneration (GTR) procedures. For more information about OraPharma, Inc. and its products, visit www.orapharma.com.
PLUS™ (resorbable collagen membrane) is used in guided bone regeneration (GBR) and guided tissue regeneration (GTR) procedures. For more information about OraPharma, Inc. and its products, visit http://www.orapharma.com.
 
About ARESTIN®
 
ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg is indicated as an adjunct to scaling
and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program which
includes good oral hygiene, and scaling and root planing.
 
ARESTIN® contains minocycline, a tetracycline derivative, and therefore should not be used in children and in pregnant or nursing women. The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of the teeth.
 
The most common treatment-emergent adverse events were headache (9.0%), infection (7.6%), flu syndrome (5.0%), and pain (4.3%). These occurred at a similar rate to SRP and SRP + placebo.
 
ARESTIN® and OSSIX™ PLUS™ are trademarks of OraPharma, Inc.
Views: 57
Sponsors
Townie Perks
Townie® Poll
Do you do more or less endo procedures since you started practicing?
  
The Dentaltown Team, Farran Media Support
Phone: +1-480-445-9710
Email: support@dentaltown.com
©2025 Dentaltown, a division of Farran Media • All Rights Reserved
9633 S. 48th Street Suite 200 • Phoenix, AZ 85044 • Phone:+1-480-598-0001 • Fax:+1-480-598-3450